


ISSN: 2249-7137

Vol. 11, Issue 10, October 2021 Impact Factor: SJIF 2021 = 7.492



ACADEMICIA An International Multidisciplinary Research Journal



(Double Blind Refereed & Peer Reviewed Journal)

DOI: 10.5958/2249-7137.2021.02290.4

CLINICAL CURRENT AND ANTI-VIRAL THERAPY OF ADENOVIRAL KERATOCONJUNCTIVITIS

Kamila Makhsudovna Imomalieva*; Shahnoza Allaberganovna Bayjanova**

*PhD, Assistant, Department of Ophthalmology, Tashkent Medical Academy, UZBEKISTAN

**Master, Department of Ophthalmology, Tashkent Medical Academy, UZBEKISTAN

ABSTRACT

This study presents the clinical efficacy of the antiviral drug "Virostav" in patients with adenoviral keratoconjunctivitis. On the background of therapy with Virostav, complete recovery with restoration of normal vision was revealed in 69.2% of patients, and partial recovery with subsequent complete restoration of vision in 30.8% of patients. The effectiveness of the drug with complete recovery of patients with adenoviral conjunctivitis was 76.9%. The convenient and ready-to-use drug Virostav has a pronounced therapeutic effect in the complex treatment of patients with both adenoviral keratoconjunctivitis and adenoviral conjunctivitis, this is the basis that the drug Virostav is promising in the treatment of patients with viral eye lesions.

KEYWORDS: Adenoviral Keratoconjunctivitis, Visometry, Interferon, Eye Drops, Virostav, Viral Eye Damage, Antiviral Drug, Biomicroscopy, Clinical Efficacy.

REFERENCES

- 1. Hillenkamp J., Reinhard T., Ross R.S. et al. The effects of cidofovir 1% with and without cyclosporin a 1% as a topical treatment of acute adenoviral keratoconjunctivitis: a controlled clinical pilot study // Ophthalmology. 2002. Vol. 109. № 5. P. 845–850.
- Huang J., Kadonosono K., Uchio E. Antiadenoviral effects of ganciclovir in types inducing keratoconjunctivitis by quantitative polymerase chain reaction methods // Clin. Ophthalmol. 2014. Vol. 8. P. 315–320.

ACADEMICIA

ISSN: 2249-7137 Vol. 11, Issue 10, October 2021 Impact Factor: SJIF 2021 = 7.492

- 3. Lenaerts L., De Clercq E., Naesens L. Clinical features and treatment of adenovirus infections // Rev. Med. Virol. 2008. Vol. 18. № 6. P. 357–374.
- **4.** Maychuk Yu.F. Modern possibilities of therapy for conjunctivitis // Proceedings of the 17th Ros. nat. Congress "Man and Medicine". M., 2011. No 2. P. 215-225.
- Nwanegbo E.C., Romanowski E.G., Gordon Y.J. et al. Efficacy of topical immunoglobulins against experimental adenoviral ocular infection // Invest. Ophthalmol. Vis. Sci. 2007. Vol. 48. № 9. P. 4171–4176.
- 6. Polymorphs and hydrates of acyclovir / K. M. Lutker, R. Quiñones, J. Xu [et al.] // J. Pharm. Sci. 2011. Vol. 100, № 3. P. 949-963.
- Uchio E., Inoue H., Fuchigami A., Kadonosono K. Anti-adenoviral effect of interferon-β and interferon-γ in serotypes that cause acute keratoconjunctivitis // Clin. Experiment. Ophthalmol. 2011. Vol. 39. № 4. P. 358–363.